JNJ - Collegium Pharmaceutical Just Updated Its 2020 Guidance. Is It a Buy?
There's plenty of interesting biotech news floating about for investors to consider, but there was one announcement this week that might have slipped under your radar. Collegium Pharmaceutical (NASDAQ: COLL), a small-cap drug developer, announced updated guidance figures for 2020, surprising many with an impressive $160 million revenue target for its flagship pain drug in 2020.
While guidance figures are definitely subject to change, this initial estimate is not only pretty darn good for a company of Collegium's size, but also suggests the company will turn a profit this year. Is this a good time to add this stock to your portfolio? Let's look at some of the details and find out.
Image source: Getty Images.